Loading...
•
Mar 31, 2023
Caribou Biosciences Q1 2023 Earnings Report
Caribou Biosciences reported financial results for the first quarter of 2023 and reviewed recent pipeline progress.
Key Takeaways
Caribou Biosciences reported a net loss of $28.0 million for the first quarter of 2023, with $291.0 million in cash, cash equivalents, and marketable securities as of March 31, 2023. The company is advancing its pipeline of allogeneic CAR-T cell therapies, including the ongoing ANTLER trial for CB-010 and the initiation of patient dosing in the CaMMouflage trial for CB-011.
CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023
CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients at dose level 1
CB-012 IND application for r/r AML planned for H2 2023
$291.0 million in cash, cash equivalents, and marketable securities as of March 31, 2023; cash runway to fund the current operating plan into 2025
Forward Guidance
Caribou anticipates several milestones in 2023, including providing a safety and efficacy update from the ANTLER Phase 1 clinical trial for CB-010 in H2 2023, providing updates on dose escalation as the CaMMouflage Phase 1 clinical trial for CB-011 advances, and submitting an IND application for CB-012 in H2 2023.
Positive Outlook
- CB-010: Caribou plans to provide a safety and efficacy update in H2 2023 from the ongoing ANTLER Phase 1 clinical trial in r/r B-NHL, including data from at least 15 patients from dose escalation with a minimum of six months follow up.
- CB-011: Caribou plans to provide updates on dose escalation as the CaMMouflage Phase 1 clinical trial in r/r MM advances.
- CB-012: Caribou plans to submit an IND application for r/r AML in H2 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...